What is the price target for RIGL stock?
12 analysts have analysed RIGL and the average price target is 47.94 USD. This implies a price increase of 86.17% is expected in the next year compared to the current price of 25.75.
RIGEL PHARMACEUTICALS INC (RIGL) Forecast, Price Target & Analyst Ratings
NASDAQ:RIGL • US7665597024
Current stock price
25.75 USD
-0.63 (-2.39%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for RIGEL PHARMACEUTICALS INC (RIGL).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 4, 2026
- Period
- Q1 / 2026
- EPS Estimate
- $0.78
- Revenue Estimate
- 64.858M
Price Target Details & History
Consensus Price Target and Range
Mean target
$47.94
Upside
+ 86.17%
From current price of $25.75 to mean target of $47.94, Based on 12 analyst forecasts
Low
$24.24
Median
$46.92
High
$74.55
Price Target Revisions
1 Month
0.00%
3 Months
3.68%
Price Target Summary
12 Wall Street analysts provided a forecast for the next 12 months for RIGL. The average price target is 47.94 USD. This implies a price increase of 86.17% is expected in the next year compared to the current price of 25.75.
The average price target has been revised upward by 3.68% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
80.00%
RIGL was analyzed by 12 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about RIGL.
In the previous month the buy percentage consensus was at a similar level.
RIGL was analyzed by 12 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-11-05 | Cantor Fitzgerald | Maintains | Neutral -> Neutral |
| 2025-11-05 | Jefferies | Upgrade | Hold -> Buy |
| 2025-10-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-06 | Cantor Fitzgerald | Maintains | Neutral -> Neutral |
| 2025-05-07 | Cantor Fitzgerald | Maintains | Neutral -> Neutral |
| 2025-03-06 | Citigroup | Maintains | Buy -> Buy |
| 2025-03-05 | B. Riley Securities | Maintains | Neutral -> Neutral |
| 2025-03-05 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-10 | Cantor Fitzgerald | Maintains | Neutral -> Neutral |
| 2024-12-10 | B. Riley Securities | Maintains | Neutral -> Neutral |
| 2024-12-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-06 | B. Riley Securities | Maintains | Neutral -> Neutral |
| 2024-11-14 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2024-11-12 | Citigroup | Maintains | Buy -> Buy |
| 2024-10-25 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-20 | Cantor Fitzgerald | Reiterate | Neutral -> Neutral |
| 2024-09-05 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-09 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-06-25 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 4, 2026
- Period
- Q1 / 2026
- EPS Estimate
- $0.78
- Revenue Estimate
- 64.858M
- Revenue Q2Q
- 21.61%
- EPS Q2Q
- 23.05%
- Number of Analysts
- 7
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
3.40%
EPS (1 Month)
0.00%
EPS (3 Months)
17.09%
Next Earnings Summary
RIGL is expected to report earnings on 5/4/2026. The consensus EPS estimate for the next earnings is 0.78 USD and the consensus revenue estimate is 64.86M USD.
The next earnings revenue estimate has been revised upward by 3.4% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 120.2M -19.44% | 116.882M -2.76% | 179.278M 53.38% | 299.06M 66.81% | 288.78M -3.44% | 324.1M 12.23% | 394.25M 21.64% | 370.1M -6.13% | 404.94M 9.41% | 460.72M 13.77% | 452.17M -1.86% | 325.79M -27.95% | |
| EBITDA YoY % growth | -53.3M -579.85% | -19.253M 63.88% | 26.42M 237.23% | 130.42M 393.64% | 97.261M -25.42% | 142.48M 46.49% | 296.82M 108.32% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -54.3M -503.33% | -20.491M 62.26% | 24.192M 218.06% | 128.98M 433.15% | 93.84M -27.24% | 112.52M 19.91% | 149.53M 32.89% | 115.14M -23.00% | 140.17M 21.74% | 167.89M 19.78% | 142.49M -15.13% | 127.3M -10.66% | |
| Operating Margin | -45.17% | -17.53% | 13.49% | 43.13% | 32.50% | 34.72% | 37.93% | 31.11% | 34.62% | 36.44% | 31.51% | 39.07% | |
| EPS YoY % growth | -3.40 -209.09% | -1.50 55.88% | 0.94 162.67% | 6.76 593.62% | 4.14 -36.48% | 4.93 18.98% | 4.98 1.07% | 4.82 -3.12% | 5.76 19.45% | 6.63 15.04% | 5.88 -11.38% | 5.25 -10.59% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | 0.78 23.05% | 1.01 -69.21% | 1.19 -18.26% | 0.90 -21.50% |
| Revenue Q2Q % growth | 64.858M 21.61% | 67.065M -34.05% | 73.44M 5.73% | 78.346M 12.24% |
| EBITDA Q2Q % growth | 21.065M 57.47% | N/A | N/A | N/A |
| EBIT Q2Q % growth | 18.842M 47.51% | 21.828M -64.28% | 25.398M -10.63% | 29.172M 22.81% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-8.59%
EPS Next 5 Year
-2.44%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
9.65%
Revenue Next 5 Year
6.25%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
91.91%
EBIT Next 5 Year
95.89%
RIGEL PHARMACEUTICALS INC / RIGL Forecast FAQ
What is the next earnings date for RIGL stock?
RIGEL PHARMACEUTICALS INC (RIGL) will report earnings on 2026-05-04.
Can you provide the consensus estimates for RIGEL PHARMACEUTICALS INC next earnings?
The consensus EPS estimate for the next earnings of RIGEL PHARMACEUTICALS INC (RIGL) is 0.78 USD and the consensus revenue estimate is 64.86M USD.
What is the expected long term growth rate for RIGL stock?
The expected long term growth rate for RIGEL PHARMACEUTICALS INC (RIGL) is 9.65%.